Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Cambridge Antibody Technology

Status and phase

Unknown

Phase 1

Conditions

Non-Hodgkin's Lymphoma

NHL

Leukemia

Treatments

Procedure: Monoclonal Antibody Therapy

Drug: CAT-8015 Immunotoxin

Procedure: Biological therapy

Drug: Immunotoxin therapy

Procedure: Antibody Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT00515892

CAT-8015-1003

Details and patient eligibility

About

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation therapy.

PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to treatment.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

DISEASE CHARACTERISTICS:

Confirmed diagnosis of B-cell non-Hodgkin's lymphoma
Measurable disease
Evidence of CD22-positive malignancy by the following criteria,
- > 30% of malignant cells from a disease site CD22+ by FACS analysis or,
- > 15% of malignant cells from a disease site must react with anti-CD22 by immunohistochemistry
Patients with indolent subtypes of CD22+ B-cell non-Hodgkin's lymphoma, including, but not limited to mantle cell lymphoma, follicular lymphoma and Waldenström's macroglobulinemia, are eligible if stage III-IV.
Patients must have failed at least two or more courses of prior standard chemotherapy and/or biologic therapy (e.g. Rituxan). Patients with progressive mantle cell lymphoma may be eligible if they have failed one prior standard therapeutic regimen.

PATIENTS CHARACTERISTICS

Performance Status

ECOG 0-2

Life Expectancy

Life expectancy of less than 6 months, as assessed by the principal investigator

Other

Patients with other cancers who meet eligibility criteria and have less than 5 years of disease free survival will be considered on a case-by-case basis
Must be able to understand and sign informed consent
Female and male patients must agree to use an approved method of contraception during the study

Exclusion criteria

History of bone marrow transplant
Documented and ongoing central nervous system involvement with their malignant disease (history of CNS involvement is not an exclusion criterion)
Pregnant or breast-feeding females
Patients whose plasma contains either a significant level of antibody to CAT-8015 as measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as measured by a competition ELISA.
HIV positive serology (due to increased risk of severe infection and unknown interaction of CAT-8015 with antiretroviral drugs)
Hepatitis B surface antigen positive
Uncontrolled, symptomatic, intercurrent illness including but not limited to: infections requiring systemic antibiotics, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements

Hepatic function: serum transaminases (either ALT or AST) or bilirubin

≥ Grade 2, unless bilirubin is due to Gilbert's disease

Renal function: Serum creatinine clearance ≤ 60mL/min as estimated by Cockroft-Gault formula

Hematologic function:

The ANC < 1000/cmm, or platelet count <50,000/cmm, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy).
A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin dependence, if it is due to disease, based on the results of bone marrow studies
Baseline coagulopathy > Grade 3 unless due to anticoagulant therapy.

Pulmonary function:

Patients with < 50% of predicted forced expiratory volume (FEV1) or <50% of predicted diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration and alveolar volume. Note: Patient with no prior history of pulmonary illness are not required to have PFTs. FEV1 will be assessed after bronchodilator therapy.

Recent prior therapy:

Cytotoxic chemotherapy, corticosteroids (except stable doses of prednisone), whole body electron beam radiation therapy, hormonal, biologic or other standard or any investigational therapy of the malignancy for 3 weeks prior to entry into the trial
Less than or equal < 3 months prior monoclonal antibody therapy (i.e. rituximab)
Patients who are receiving or have received radiation therapy less than 3 weeks prior to study entry will be not be excluded providing the volume of bone marrow treated is less than 10% and also the patient has measurable disease outside the radiation port
Any history of prior pseudomonas-exotoxin immunotoxin (PE) administration.